Recent research has linked ALYREF to the development of various tumors, including bladder cancer [47,48], breast cancer [49], neuroblastoma [50], hepatocellular carcinoma [51,52], glioblastoma [53], and non-small cell lung cancer [54]. Here, ALYREF is linked to hepatocellular carcinoma.